CHARLOTTE – Novo Nordisk’s shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group’s Clayton plant, citing sources.
Novo Nordisk declined to comment on the report, but said in an emailed statement that the site was “running and producing for the market.”
